Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
Kristin Jensen / healthcaredive - A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.
AI Summary: Moderna has initiated a clinical trial of an mRNA vaccine targeting a potentially pandemic bird‑flu strain, joining global efforts to have a rapid‑response countermeasure ready. Regulators and public‑health experts hail the move as sensible pre‑emptive science—because nothing says “we planned for this” like testing the vaccine before the outbreak arrives.
Related Stories
Dual Lassa–rabies vaccine phase 1 shows safety in humans / 2 months
DR Congo Ebola outbreak tops 3,000; Bundibugyo vaccine trial begins / 4 wks
Pfizer's Lyme vaccine heads to FDA after mixed trial results / 5 months
Experimental plague vaccine protects immune‑deficient mice from pneumonic plague / 5 wks
UK begins human testing of first AI-designed 'universal' vaccine / 2 months
Favipiravir shows promise in Lassa fever Phase 2 trial / 3 months
Engineered 15‑strain biotherapeutic matches donor FMT for C. difficile / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare, Olfaction, Autism, CDC and look for the RSS link.
StackHealth Time Machine